论文部分内容阅读
急性肺损伤(ALI)是多种原因诱发的肺部过度炎症反应,其发病率和死亡率均较高。由于其发病机制复杂且并未完全阐明,至今仍无特效救治药物。许多研究表明补体活性成分补体5a(C5a)及其受体的激活在ALI的发生过程中是必需的,以C5a及其受体作为靶点的药物研发有望为ALI的治疗带来新的希望。该文对C5a参与ALI的实验证据和可能的作用机制进行了综述。
Acute lung injury (ALI) is a multifactorial pulmonary inflammatory response that has a high morbidity and mortality. Because of its complicated pathogenesis and incomplete elucidation, there are still no effective remedial drugs. Many studies have shown that the activation of the complement complement 5a (C5a) and its receptor is necessary during the development of ALI. The development of drugs targeting C5a and its receptor is expected to bring new hope for the treatment of ALI. This article reviewed the experimental evidence and possible mechanism of C5a involved in ALI.